Iovance Biotherapeutics Inc

Discover how Iovance Biotherapeutics leverages tumor‑infiltrating lymphocytes (TILs) to pioneer personalized cancer immunotherapies, market challenges, and future growth prospects.

Iovance Biotherapeutics Inc’s stock price plummeted to a new 52-week low, sparking concerns among investors and analysts, amidst a series of downgrades and lowered price targets.

Iovance Biotherapeutics’ stock has faced significant challenges in 2025, including a decline in Q1 performance, annual maintenance report discrepancies, and analyst downgrades, leading to a new 52-week low and market skepticism.